Cardiff Oncology Inc
NASDAQ:CRDF
Intrinsic Value
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. [ Read More ]
The intrinsic value of one CRDF stock under the Base Case scenario is 0.07 USD. Compared to the current market price of 3.99 USD, Cardiff Oncology Inc is Overvalued by 98%.
Valuation Backtest
Cardiff Oncology Inc
Run backtest to discover the historical profit from buying and selling CRDF stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cardiff Oncology Inc
Current Assets | 77.4m |
Cash & Short-Term Investments | 74.8m |
Receivables | 288k |
Other Current Assets | 2.3m |
Non-Current Assets | 4.2m |
PP&E | 2.9m |
Other Non-Current Assets | 1.3m |
Current Liabilities | 10.4m |
Accounts Payable | 2m |
Accrued Liabilities | 8.5m |
Non-Current Liabilities | 1.5m |
Other Non-Current Liabilities | 1.5m |
Earnings Waterfall
Cardiff Oncology Inc
Revenue
|
488k
USD
|
Operating Expenses
|
-45.9m
USD
|
Operating Income
|
-45.4m
USD
|
Other Expenses
|
3.9m
USD
|
Net Income
|
-41.5m
USD
|
Free Cash Flow Analysis
Cardiff Oncology Inc
CRDF Profitability Score
Profitability Due Diligence
Cardiff Oncology Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Cardiff Oncology Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
CRDF Solvency Score
Solvency Due Diligence
Cardiff Oncology Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Cardiff Oncology Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRDF Price Targets Summary
Cardiff Oncology Inc
According to Wall Street analysts, the average 1-year price target for CRDF is 10.71 USD with a low forecast of 7.07 USD and a high forecast of 14.7 USD.
Ownership
CRDF Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CRDF Price
Cardiff Oncology Inc
Average Annual Return | 276.66% |
Standard Deviation of Annual Returns | 689.19% |
Max Drawdown | -96% |
Market Capitalization | 178.3m USD |
Shares Outstanding | 44 677 200 |
Percentage of Shares Shorted | 7.86% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2004-07-27. The firm is focused on developing treatment for cancer patients. Its drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. Its clinical trial includes TROV-054, CRDF-001 and TROV-053. TROV-054 is a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). TROV-053 is a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone. CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Contact
IPO
Employees
Officers
The intrinsic value of one CRDF stock under the Base Case scenario is 0.07 USD.
Compared to the current market price of 3.99 USD, Cardiff Oncology Inc is Overvalued by 98%.